Dabigatran Following Transient Ischemic Attack and Minor Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT02295826

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02295826
Other papers using this trial's data
  • Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke Stroke, 2020-04 DOI, PubMed 32098609

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02295826. Randomized; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2018-12-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dabigatran Following Transient Ischemic Attack and Minor Stroke
Acronym
DATAS II
Condition
Minor Ischemic Stroke
Intervention (Drug)
Dabigatran
Intervention (Drug)
Acetylsalicylic acid
Lead sponsor
University of Alberta (class: other)

Record details

Record id
cardio:ct-nct02295826
Content hash
01d19ee196b19132efa1fd24674c5d08676cf5ab884a110b8cfe3ffc8762a5ea